Determination of the in vitro activity of experimental antifungal substances against fungal pathogens, including the fungal species identified in table 1 below, as well as toxicity of a subset of…
Active Awarded
- Contract number
- 75N93026F00001
- Awardee
-
The University Of Texas Health Science Center At San Antonio UEI C3KXNLTAAY98
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $91,309
Award facts
- Opportunity
-
- A31 Solicitation number
- Contract value 50% obligated
-
- $91,308.51 Current, with exercised options
- $182,617.02 Potential, with all options
- Completion date 77% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- San Antonio, TX 78229, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $182,617.02 delivery order to The University of Texas Health Science Center at San Antonio (UTHSCSA) on January 14, 2026, with completion targeted for January 13, 2027. This firm fixed-price contract falls under the In Vitro Screening for Antifungal Activity Against Fungal Disease Pathogens program and requires UTHSCSA to determine the in vitro activity of experimental antifungal substances against specified fungal pathogens, as well as assess the toxicity of a subset of these compounds in mammalian cell assays. The work will be performed in San Antonio, Texas. No socioeconomic set-aside was used for this award, reflecting UTHSCSA's capacity to compete in full and open procurement.
This delivery order is issued under the In Vitro Assessments of Antimicrobial Activity (IVAAA) master contract vehicle, part of UTHSCSA's broader $146.3 million, seven-year Indefinite Delivery Contract with NIAID focused on Pre-Clinical Models of Infectious Diseases through July 2031. UTHSCSA's established expertise in infectious disease research, coupled with its track record of delivering specialized laboratory services and preclinical assessments for NIAID, positions the institution to support the agency's antimicrobial drug development pipeline and pandemic preparedness initiatives. The institution's prior task orders under this vehicle have supported candidate testing in murine models of fungal infections and in vitro assessments of antimicrobial activity, with individual orders valued at over $1.2 million for specialized research activities.
Description
Determination of the in vitro activity of experimental antifungal substances against fungal pathogens, including the fungal species identified in table 1 below, as well as toxicity of a subset of these antifungal substances in mammalian cell assays.
Quick answers
Who was awarded contract 75N93026F00001?
75N93026F00001 was awarded to The University Of Texas Health Science Center At San Antonio by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 14, 2026.
How much is contract 75N93026F00001 worth?
The government has obligated $91,309 on 75N93026F00001. Its potential value, with all options, is $182,617.
Is contract 75N93026F00001 an order under another contract?
Yes. 75N93026F00001 is a delivery order under 75N93019D00022, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93026F00001 competed?
The extent of competition for 75N93026F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award